HHM Global | B2B Online Platform & Magazine http://www.hhmglobal.com Hospital & Healthcare Management is a leading B2B Magazine & an Online Platform featuring global news, views, exhibitions & updates of hospital management industry. Wed, 26 Sep 2018 08:59:39 +0000 en-US hourly 1 https://wordpress.org/?v=4.9.8 Keynote Announcement – JPMorgan Chase – Jeffery Davis, Executive Director, Operational Excellence http://www.hhmglobal.com/knowledge-bank/news/keynote-announcement-jpmorgan-chase-jeffery-davis-executive-director-operational-excellence Tue, 25 Sep 2018 08:50:07 +0000 http://www.hhmglobal.com/?p=15522 Jeff’s operational excellence career spans nearly 29 years including nearly 6 years with JPMorgan Chase, 11 years with Toyota and 12 years of external consulting.

Jeff leads global teams of vice presidents, project managers and associate consultants to create and deploy best practices rooted in Lean & Six Sigma across the world’s leading financial services corporation. Target areas of improvement include risk, customer experience, delivery, cost and employee engagement.

BTOES is the USA’s Primetime Business Transformation & Operational Excellence event, with 150+ speakers expected, below are the first 50+ speakers already confirmed:

World Alzheimer’s Day; celebrate to create awareness about the disease and to reduce the, stigmatization and lack of information surrounding dementia http://www.hhmglobal.com/industry-updates/press-releases/world-alzheimers-day-celebrate-to-create-awareness-about-the-disease-and-to-reduce-the-stigmatization-and-lack-of-information-surrounding-dementia Fri, 21 Sep 2018 07:06:36 +0000 http://www.hhmglobal.com/?p=15411 Aware Gleneagles Global Hospital, L B Nagar celebrates the World Alzheimer’s Day today. September 21st 2018 is the 7th World Alzheimer’s Day – the movement was propelled in 2012. From various studies it is established that on average 2 out of 3 people globally have little or no understanding of Alzheimer’s disease and related dementia in respective countries.

It’s essential to celebrate this day to create awareness about the disease and to reduce the, stigmatisation and lack of information surrounding dementia.

Most people often think that this disease is a normal part of ageing. Though this may not be true, a greatest risk factor for Alzheimer’s disease is increasing age. This is evident by majority of Alzheimer’s patients being 65 years or older. This doesn’t completely classify the disease as an elderly disease. This is because there are many people under 65 who are suffering from disease.

Alzheimer’s disease is the most common cause of dementia. It destroys brain cells and nerves disrupting the transmitters which carry messages in the brain, particularly those responsible for storing memories.

During the course of Alzheimer’s disease, nerve cells die in particular regions of the brain. The brain shrinks as gaps develop in the temporal lobe and hippocampus, which are responsible for storing and retrieving new information. This further affects people’s ability to remember, speak, think and make decisions. The production of certain chemicals in the brain, such as acetylcholine is also affected. The cause for the death of nerve cell  is not identified but there are characteristic appearances of the brain after death. In particular, ‘tangles’ and ‘plaques’ made from protein fragments are observed under the microscope in damaged areas of brain. This confirms the diagnosis of Alzheimer’s disease.

Characteristically, the beginning of Alzheimer’s disease is lapses of memory, struggle in finding the right words for everyday objects or mood swings. As Alzheimer’s progresses, the person may:

  • Routinely forget recent events, names and faces and have difficulty in understanding what is being said
  • Experience personality changes, appearing to no longer care about those around them
  • May have mood swings and burst into tears for no seeming reason, or believe that someone is trying to harm them

In advanced cases people may also:

  • Adopt unsettling behaviour like getting up in the middle of the night or wander off and become lost
  • Lose their inhibitions and sense of suitable behaviour, undress in public or make inappropriate sexual advances.

Early symptoms
Every person is unique in one way or another. In the same way Dementia affects people differently – no two people will have symptoms that develop in exactly the same way as the other. An individual’s personality, general health and social situation are all important factors in determining the impact of dementia on him or her.

The most common early symptoms of Dementia are as follows :

  • Loss of memory
  • Trouble in doing day todayerrands
  • Difficulties with linguistic
  • Confusion of time and place
  • Poor or decreased judgment
  • Difficulty in the sequences of day to activities
  • Keeping things and forgetting where they are kept
  • Changes in mood or behaviour
  • Changes in character

A person with dementia may seem different from his or her usual self in ways that are difficult to pinpoint. A person may become suspicious, irritable, depressed, apathetic or anxious and agitated especially in situations where memory problems are causing difficulties.

There is no prevention for the disease but if the precautions are taken and if a person adheres to the healthy lifestyle and stop smoking, consuming alcohol and keep Blood Pressure and Sugar under control   the onslaught can be postponed.

The important factor in the disease is that the patient’s family members have to be educated to take care of the patient which will decreases the suffering to certain extent and the life can become bearable for the patient.

Top Digital Health Trends in 2019: Perspectives from HIMSS Leaders http://www.hhmglobal.com/knowledge-bank/techno-trends/top-digital-health-trends-in-2019-perspectives-from-himss-leaders Thu, 20 Sep 2018 08:39:01 +0000 http://www.hhmglobal.com/?p=15398 From a global perspective, 2019 is going to be the year when digital health care starts to come of age. This is akin to going on a first date; it brings with it the similar feelings of excitement, energy and discovery – along with the growing pains of adolescence.

Like adolescence, it may not start off as a smooth ride. One can foresee different pressures already starting to appear during times when digital solutions quickly evolve, with expectations to deliver on their promises.

Different countries are at different stages in this global digital journey towards a more data driven, personalised, patient-centric health and care system: one which complements what matters to patients, providers and others leading and supporting the delivery of optimal health and care.It is likely we will see some notable successes to start. We can expect to catch a glimpse of highly anticipated outcomes in the use of artificial intelligence (AI) and machine learning – both in terms of prediction as well as execution. Areas like radiology and basic management of uncomplicated non-communicable diseases will also start to endure fundamental business redesign to cope with the inevitable changes to workflows. Added to this, we will see the first glimpses of precision medicine in action with the start of deployment around biologics at scale.

We can also expect to see more questioning around the whole basis and structure behind traditional evidence-based care, which has really underpinned our advances in medicine in the early 21st century. The start of a movement from evidence-based care for all to a more personalised “evidence-based” approach utilising real world approaches is likely, facilitated by secure cloud-based technology.

Although in 2018 we’ve witnessed an increased focus on reducing clinician and physician burden, the pressure remains to quickly on adapt to these changes. There is an expectation to personalise care within imperfect health and care systems, in addition to addressing greater complexity inherent in multi-morbidity.

This burden is also amplified by the increasing tension between the importance of comprehensive and accurate concurrent data entry. It will be a time to form new relationships with patients based on new approaches to traditional episodic directive types of care. These physician and patient relationships should be more akin to partnerships; especially around interactions pertaining to lifelong non-communicable diseases.

Thus, there is heightened potential for products which would manage the issues of data and administration for clinicians, whether using voice as a technology or AI. There is potential for digital technologies to mature enough to better manage the whole new explosion of digital alerts, which physicians are all too often confronted with.

Additionally, there is potential for digital technology to do more of what it was initially designed to do: act as a clinical extender, assisting patients in achieving health outcomes and creating a healthier work-life balance for doctors to mitigate the stress levels inevitably contributing to burnout.

HIMSS has an important part to play in supporting physicians’ understanding of digital health as a lever to the transformation of health and care. As partners in their journey, we can help point them to solutions and encourage a more conducive environment for all of us – patients, doctors and the entire health system as a whole.

Charles Alessi is a moderator at HIMSS AsiaPac18 in Brisbane this November. To learn more about this event and take advantage of the early bird promo rates, click here.

Oceasoft launches cobalt x2, its new-generation system For monitoring physical parameters http://www.hhmglobal.com/industry-updates/press-releases/oceasoft-launches-cobalt-x2-its-new-generation-system-for-monitoring-physical-parameters Thu, 20 Sep 2018 07:32:51 +0000 http://www.hhmglobal.com/?p=15384 With its Cobalt X2 product launch, OCEASOFT brings a new dimension to solutions for monitoring physical parameters such as temperature, humidity, and more. Cobalt X2 focuses on simplifying and safeguarding daily monitoring operations for life science professionals.

OCEASOFT worked closely with the Fondation Jean-Dausset-CEPH international genetic research center, located in France, to carry out preliminary testing and develop a product that truly matches user needs.

15384 - Cobalt_-X2.jpg“We designed Cobalt X2 so that our customers could focus on their core activity and spend less time monitoring physical parameters that affect their products,” explains Laurent Rousseau, CEO of OCEASOFT.

OCEASOFT created its new Cobalt X2 system for monitoring physical parameters to meet major challenges faced by life science professionals, including laboratories, hospitals, and pharmaceutical companies:

Oceasoft Cobalt X2 system

Simple to set up and use
Cobalt X2 simplifies daily tasks for users by enabling them to acknowledge alarms directly via the module’s color touch-screen. Cobalt X2 also serves as a data collector and gateway for OCEASOFT’s wireless sensors, further simplifying installation with automatic connection.

Robust wireless performance
Integrating LoRaWAN™ long-range connectivity, Cobalt X2 modules communicate wirelessly over very large sites and inside buildings easily, benefiting from completely automated deployment. Cobalt X2 features distinct sensor channels to support any combination of up to four wired Smart-Sensors (with calibration parameters stored directly on-board) or wireless Bluetooth® enabled sensors, giving users a cost-effective way to monitor up to four different pieces of equipment with a single module.

Helping ensure your product quality and compliance
Cobalt X2 includes features designed specifically to respect applicable sector-related regulations: 21 CFR Part 11, EN 15189, and good practices guidelines (GxP). To ensure optimal service to customers, OCEASOFT has its own sensor calibration laboratory, accredited according to the ISO 17025 standard.

Cobalt X2 beta tester: Fondation Jean Dausset-CEPH, France
Hélène Blanché-Koch, Head of Biological Resources Centre at Fondation Jean Dausset-CEPH (Human Polymorphism Study Center), was pleased to work with OCEASOFT through the design and testing phases of the new Cobalt X2 product: “We talked extensively before moving ahead with testing. We shared our issues and needs with OCEASOFT and discussed various development options. Our collaboration lasted several months before we actually started testing at our facility.”

Tests were carried out in several steps from November 2017 to June 2018.

“By setting up Cobalt X2 modules, we can now manage alarms remotely using a smartphone, which is an undeniable benefit for us in terms of protection and operational practicality, especially for on-call staff. In addition, we can handle installation by ourselves, unlike a previous system that required our IT department to get involved to manage a special temperature server,” adds Hélène Blanché-Koch.

New-generation Cobalt X2 solution: monitoring system overview

Key benefits

  • LoRaWAN™ long-range wireless communication technology
  • Data collection on up to 4 distinct sensor channels, any combination of Bluetooth®-enabled OCEASOFT sensors and wired OCEASOFT Smart-Sensors (with calibration parameters stored in their own memory to simplify recalibration)
    2.4″ color touch-screen for easy interaction and control
  • Powered by USB port (with AC adapter) or battery
  • Low power consumption
  • For use with various sensors, including: temperature, humidity, %CO2, 4-20 mA, 0-5 V, 0-10 V, dry contact
  • Comprehensive web application

Cobalt X2 solution flow:15384 - Cobalt-X2-solution-flow.jpg

Stakes that demand relevant solutions
Traceability, quality control, and ensuring optimal storage and transport conditions for health products have become critical issues in the life science sector:

“In 2018, half of the 350 most sold medical drugs in the world will be temperature sensitive. Measuring, controlling, and generating alerts regarding these products’ real storage and transport conditions are key requirements for obvious reasons of efficiency, patient safety, and of course, economic considerations,” concludes Laurent Rousseau.

Australian Success: HIMSS-Elsevier Highlights from Down Under http://www.hhmglobal.com/industry-updates/press-releases/australian-success-himss-elsevier-highlights-from-down-under Thu, 20 Sep 2018 06:02:24 +0000 http://www.hhmglobal.com/?p=15361 The 6th Annual HIMSS-Elsevier Asia Pacific Digital Healthcare Award is open for submissions! Held as part of the HIMSS AsiaPac18 conference, the Award will be presented for the first time in Australia. Let’s take a look at past HIMSS-Elsevier Digital Healthcare Award success stories from Down Under.

This Global Award has attracted 178 submissions across 29 countries and 99 unique organisations since it began in 2013. Learn more about it here.

15361 - Princess_Alexandra_Hospital.jpgPrincess Alexandra Hospital, Brisbane, Queensland
Implemented in March 2017, Prince Alexandra Hospital (PAH)’s integrated EMR (ieMR) was a 5th Year Special Winner under the Outstanding ICT Innovation Award Category for the HIMSS-Elsevier Digital Healthcare Award 2017.

Using intelligent analytics as a driver for change, the ieMR provided rich data to assist healthcare providers with real-time and near real-time access to clinical and operational information to improve the quality and efficiency of care.The data analytics project which was co-led by clinicians and data analysis experts, produced interactive dashboard prototypes to extract clinically meaningful data from the ieMR and presented the information in a way that was understood by clinicians.

Some of the beneficial clinical and operational outcomes include:

  • Reduction in Emergency Department re-admissions by 45%
  • Reduction in pathology turnaround time in the Emergency Department across all types of tests by 5 – 21% and across hospital average by 22% Increase in rapid response by 45%
  • Reduction in cardiac arrests (15 fewer than predicted)

Royal Children’s Hospital, Melbourne, Victoria
A nominee for the Outstanding ICT Innovation Award Case Study Category for the HIMSS-Elsevier Digital Healthcare Award 2017, the Whatsapp Go Live Project by the Royal Children’s Hospital (RCH) Melbourne began as an experiment to connect EMR Super Users and EMR experts. Providing EMR ‘know-how’ via the Super User network reduced the calls to Help Desk and generated a positive impact on the build team’s ability to resolve tickets. In the first three weeks, the ticket resolution rate was at well over an unprecedented 90%.

The successful use of social media has continued into the business as usual environment and continues to be used for end-user support and as a channel of communication between members of the EMR team

Sydney Children’s Hospital Network (SCHN), Sydney, New South Wales
15361 - sydney_hosp.jpgImplemented in May 2017 by the Sydney Children’s Hospital Network (SCHN), the My Health Memory (MHM) outpatient mobile phone application (app) was also another nominee for the Outstanding ICT Innovation Award Case Study Category for the HIMSS-Elsevier Digital Healthcare Award 2017. The MHM app is a patient facing portal that is integrated with the Network’s electronic medical record (eMR).

The MHM App provides patients, families and proxy carers access to communicate with staff via the secure messaging tool, embedded into the eMR (Cerner) the communication conversation once complete automatically becomes a note in the eMR supporting shared care.

App users can also view appointment schedules, receive notifications related to the specific appointment type, request appointment reschedules and participate in telehealth conferences, and make their own notes. Carers can use the App to manage the care of multiple children and document personal information in the “about me” profile section of the App.

Fiona Stanley Hospital, Perth, Western Australia
15361 - Fiona_Stanley_Hospital.jpgFor the HIMSS-Elsevier Digital Healthcare Award 2016, Fiona Stanley Hospital’s (FSH) (Perth, Australia) Telehealth Team submitted a case study of their data-driven approach towards telehealth services .

The new method involved using data analysis to identify rural patients who might be suitable for a remote consultation rather than a face-to-face visit at FSH. Particular emphasis was given to Indigenous Australians, socioeconomically disadvantaged people, people living in rural and remote areas as well as those with disabilities, who can benefit the most from telehealth services.

Results from the data-driven approach include:

  • Increased telehealth usage by 325% from approximately 80 appointments per month to over 340
  • Did not attend rate at 11% compared to the average outpatient clinic rate of 30%
  • Saved patients a total of 2762 days away from home

St Stephen’s Hospital Hervey Bay, Hervey Bay, Queensland
15361 - St-Stephens-Hospital.jpgSt Stephen’s Hospital in Hervey Bay (SSHB) was a recipient of the Outstanding ICT Achievement Award for the HIMSS-Elsevier Digital Healthcare Award in 2015 for its eHealth Unite Project. The eHealth initiative for SSHB consisted of the development, procurement, purchase, supply, installation configuration, testing, implementation and commissioning of IT equipment, software and associated workflows in the new hospital building. SSHB’s end-to-end solution consists of 29 Cerner applications, 20 integrated devices and five major interfaces including: Closed-loop medication management, EMR and clinical interface and an integrated patient system

Some of the initial benefits of the project include:

  • An average of 87% for clinic adoption rates two weeks post opening and have remained consistently high even without registrars onsite
  • The Hospital Administration Booking System (HABS) has improved the time required to admit a patient from 10 minutes to two minutes, demonstrating a saving of eight minutes per hospital admission

Macquarie University Hospital15361 - Macquarie_University.jpgMacquarie University Hospital (MUH) submitted their case study of being a market leader in digitalising the healthcare environment for the HIMSS-Elsevier Digital Healthcare Award in 2013.

A suite of applications was implemented to enable a seamless patient journey from pre-admission through to discharge was deployed throughout the hospital. Staff efficiency and centralised organizational data has been managed through key applications housed on enterprise class hardware in a virtualised environment across two data centres.

The clinical systems provide a complete, secure EMR across all the functions of the hospital from inpatient management to device integration and business intelligence.

MUH also provides additional training avenues for staff through utilising eLearning facilities. The “log on”, however, adds another step and some time to each process as staff move through their daily activities.

MUH has put in place a number of initiatives to reduce this burden on those processes and staff:

  • A “Single Sign On” utility automatically signs in to core clinical systems and brings patient context between them
  • Sub “10-second” log on has been achieved at all bedside cockpits and rolling out to some workstations
  • Tablets have been trialed successfully for high-speed / volume processes such as medication rounds

We are inviting all healthcare providers in Australia and the APAC region to submit your best case studies for the HIMSS-Elsevier Asia Pacific Digital Healthcare Award. Categories open for submission are: Outstanding ICT Achievement and Outstanding ICT Innovation. Submit and showcase your projects here

PMR predicts that the immune checkpoint inhibitors will present lucrative opportunities to investors in the near future http://www.hhmglobal.com/knowledge-bank/industry-reports/pmr-predicts-that-the-immune-checkpoint-inhibitors-will-present-lucrative-opportunities-to-investors-in-the-near-future Wed, 19 Sep 2018 11:44:28 +0000 http://www.hhmglobal.com/?p=15355 Attributed to growing demand for the development of biologics targeting cancer therapy, PMR predicts that the immune checkpoint inhibitors will present lucrative opportunities to investors in the near future – as quoted by a research expert at Persistence Market Research (Healthcare & Life Sciences).

Expanding at a booming CAGR of 14.6%, the global market for immune checkpoint inhibitors market is expected to reach a value beyond US$ 35 Bn over 2018-2026. Growing prevalence of various types of cancers and expanding healthcare expenditure will remain the most prominent drivers of immune checkpoint inhibitors market over the forecast period.

Besides cancer prevalence, increasing FDA approvals and growing use of immune-oncology products in treating cancers will also push the demand for immune checkpoint inhibitors in the near future. However, high price point associated with both drug development and treatment will continue to restrict adoption. Frequently observed last stage failure will also remain a major concern in the long run.

“Our extensive company share analysis predicts that the top two players in the global immune checkpoint inhibitors market currently hold a massive revenue share of over 95%. Based on the exhaustive assessment of each drug class in the global immune checkpoint inhibitors market, we arrived at the forecast that the PD-1 will continue dominance in the market, primarily attributed to rapid FDA approvals to PD-1 products,” explained an expert senior research analyst working with the healthcare and life sciences domain at Persistence Market Research.

FDA Approvals Continue to Encourage North American Market for Immune Checkpoint Inhibitors
North America is likely to continue monopoly in the global market for immune checkpoint inhibitors with over 65% share of the total market revenue. Large number of FDA approvals, expanding application base in treatments for various cancer types, and increasing combination drug approvals will play a pivotal role in shaping the market for immune checkpoint inhibitors in North America. According to PMR’s regional analysis of global immune checkpoint inhibitors market, Asia Pacific will demonstrate vigorous growth throughout the projection period – at the double digit CAGR of over 17%.

High Potential Combination Therapies to Open New Doors of Opportunities
With a strong reference post success of the promising results delivered by Bristol-Myers Squibb using a combination of Yervoy and Opdivo, the market for immune checkpoint inhibitors has been witnessing several more combination therapy products in the pipeline. Such a scenario is responsible for the current situation of the immune checkpoint inhibitors marketplace that reflects a major paradigm shift of companies from conventional mono-therapies to combination therapies for better end results.

While a considerable number of combination therapies introduced by various companies have been successfully contributing to the efforts in transforming oncology, the global market for immune checkpoint expects successful introduction of more such therapies. One of those in the pipeline includes the combination with target specific mAbs, chemotherapy, and other checkpoint inhibitors.

Key Players to Invest Efforts in Developing Products to Traverse Diverse Indications
The global immune checkpoint inhibitors market is competitive yet consolidated due to strong presence of established players; however, a few prominent brands such as Tecentriq have strategically maintained a consistent position in the market since their first product launch. A majority of leading players participating in the global immune checkpoint inhibitors marketplace are concentrating on incorporating value addition programs for regulating the customer base through enhancement of product offerings to suit a diverse range of indications.

Established companies in the global immune checkpoint inhibitors market landscape are striving to enhance therapeutic applications of their existing product offerings. Moreover, a number of key players are also eyeing the high potential markets emerging in developing countries such as KSA and South Africa by seeking FDA approvals to their products in these markets.

UK’s NHS Supply Chain orders Elekta brachytherapy equipment for accurate cancer treatment http://www.hhmglobal.com/industry-updates/press-releases/uks-nhs-supply-chain-orders-elekta-brachytherapy-equipment-for-accurate-cancer-treatment Wed, 19 Sep 2018 08:22:27 +0000 http://www.hhmglobal.com/?p=15457 Elekta announced that the UK’s National Health Service (NHS) will acquire 10 Flexitron®  afterl oading platforms used to treat a variety of the most common cancers with brachytherapy.

The systems have been ordered by the NHS Supply Chain and the order will be booked in the second quarter of Elekta’s fiscal year 2018-19.

Brachytherapy is a highly targeted form of radiotherapy where a radiation source is placed inside or next to the area that requires treatment. It is commonly used to treat cancers of the cervix, prostate, breast, and skin. When used as a boost in combination with external beam radiation therapy, brachytherapy historically has increased survival rates significantly.

Flexitron provides patients with the most sophisticated and safe brachytherapy procedure possible, while clinicians benefit from a simpler, more intuitive brachytherapy workflow.

Steve Tomkins, Elekta’s Business Unit Manager for UK, Ireland and Nordics, said: “We are very happy that the NHS is investing in this essential treatment modality – brachytherapy can offer unsurpassed accuracy and efficiency in treatment delivery. And through the NHS Supply Chain, this equipment can be utilized by both existing customers as well as clinics with competing systems as they are replaced.”

Steve added: “Elekta is the market leader for brachytherapy solutions both in the UK and globally, a position gained through our demonstrated commitment and innovation. In addition to Flexitron, Elekta also offers our new Venezia gynecological applicator for patients with advanced cervical cancer. Both these systems are supported by Elekta’s BrachyAcademy, an educational program to advance the successful use of brachytherapy.”

To learn more, visit elekta.com/flexitron.


Hitachi’s First Dedicated Compact Proton Therapy System to be Supplied to Tokushukai Medical Group http://www.hhmglobal.com/industry-updates/press-releases/hitachis-first-dedicated-compact-proton-therapy-system-to-be-supplied-to-tokushukai-medical-group Wed, 19 Sep 2018 07:19:34 +0000 http://www.hhmglobal.com/?p=15351 Hitachi, Ltd. announced that it has received an order for the compact proton therapy system from Tokushukai Medical Group, and the system will be installed at Shonan Kamakura Advanced Medical Center, which is planned to be built near Shonan Kamakura General Hospital. This is the first order for Hitachi’s dedicated compact proton therapy system.

Following the expansion of demand for proton therapy system with minimized footprint worldwide, Hitachi has developed dedicated single room proton therapy system (Single Room Solution).

Single Room Solution features optimized system configuration, reducing the footprint to 70% of conventional solution, realizing installation in urban limited areas and contributing to lower the initial cost and shorten the lead time. Other features include spot scanning technology for treating certain forms of cancer and full rotating gantry with cone beam CT for precise patient positioning, sustaining high performance technologies in minimized footprint.

Tokushukai Medical Group, operating 339 medical facilities in Japan, is planning to build Shonan Kamakura Advanced Medical Center near Shonan Kamakura General Hospital, targeting to complete in September 2020. Four-story building with one basement floor will be comprehensive center for proton therapy, BNCT (Boron Neutron Capture Therapy), RI (Radioisotope) therapy and drug discovery research and support through the use of PET (Positron Emission Tomography).

Hitachi has been proactively promoting particle therapy business worldwide, supplying world-class facilities around the world with its highly reliable and proven particle therapy systems, which have treated more than 16,000 patients, and integrating Mitsubishi Electric Corporation’s particle therapy system business in June 2018. Under the new organization, Hitachi will provide products and services with higher performance and added value, including Single Room Solution and hybrid system combined with capability of proton and heavy ion therapy.

As Hitachi expands its healthcare business, it will continue to accelerate the globalization of its particle therapy system business and contribute to cancer treatment around the world.

Single Room Solution will be introduced at the American Society for Radiation Oncology (ASTRO) Annual Meeting to be held in San Antonio from October 21, 2018.

Overview of Particle Therapy
Particle Therapy is an advanced type of cancer radiotherapy. Protons extracted from hydrogen atoms, or carbon ions are accelerated up to 70% of the speed of light. This energy is concentrated directly on the tumor while minimizing radiation dose to surrounding healthy tissue. Particle therapy improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared to that of traditional radiotherapy. In most cases, patients can continue with their normal daily activities while undergoing treatment.

Global Carpal Tunnel Release Systems Market to Reach US$ 839.1 Mn by 2028 end Owing Rising Adoption of Surgical Procedures http://www.hhmglobal.com/knowledge-bank/industry-reports/global-carpal-tunnel-release-systems-market-to-reach-us-839-1-mn-by-2028-end-owing-rising-adoption-of-surgical-procedures Wed, 19 Sep 2018 05:53:35 +0000 http://www.hhmglobal.com/?p=15342 According to the latest market report published by Future Market Insights titled ‘Global Market Study on Carpal Tunnel Release Systems: Endoscopic carpal tunnel release systems segment projected to witness the highest growth over the forecast period. The global carpal tunnel release systems market is projected to expand at a CAGR of 5.5% during the forecast period 2018–2028 and reach US$ 839.1 Mn by the end of 2028.

Market Dynamics
The per capita healthcare expenditure is currently following an uptrend across both developed and developing economies, which is expected to increase the need for quality patient care treatment options. The growing awareness regarding carpal tunnel surgery is expected to fuel the demand for carpal tunnel release systems in the global market. The demand for carpal tunnel release systems is primarily emanating from countries such as the U.S. Germany, the U.K. and Australia due enhanced emergency room coupled with affordability are factors contributing to growing demand for better quality surgical procedure which is responsible for the growth of carpal tunnel release systems market.

The leading manufacturers are also collaborating with contract manufacturing organizations for the development of efficient carpal tunnel release systems according to desired product requirements with the belief and determination. The availability of efficient products for the carpal tunnel release surgery is expected to create enormous growth opportunities for the global carpal tunnel release systems market. However, endoscopic surgery is more costly compared to open surgery, owing to which it is not affordable for all the patients. But, over the last decade the number of surgeries by endoscopic carpal tunnel release system have been increased significantly.

Market Forecast
The global carpal tunnel release systems market is segmented on the basis of product type, end user and region. On the basis of product, the market has been segmented into open carpal tunnel release systems and endoscopic carpal tunnel release system. Open carpal tunnel release system segment is expected to remain the leading segment in the global carpal tunnel release systems market, registering a CAGR of 4.5% in terms of value over the forecast period.

The advance features of endoscopic carpal tunnel release systems will lead to increased demand over the forecast period. The endoscopic carpal tunnel release systems segment is projected to reach a market valuation of US$ 237.8 Mn by 2028 end. Endoscopic carpal tunnel release systems segment is projected to grow at faster rate than open carpal tunnel release systems for global carpal tunnel release systems market over the forecast period.

On the basis of end user, the market has been segmented into hospitals, ambulatory surgical centers and specialty clinics. Hospitals segment by end user is expected to dominate the global carpal tunnel release systems market in 2018 due to huge number of patient visit hospital for the treatment of carpal tunnel syndrome.

Ambulatory surgical center segment is projected to grow at faster rate for global carpal tunnel release systems market over the forecast period owing to increasing demand for out-patient surgical procedures. The ambulatory surgical center segment is estimated to account a value share of 35.7% of the global carpal tunnel release systems market by 2017 end and it is expected to gain market share of 46.1% by 2028 end for the global carpal tunnel release systems market.

On the basis of region, the market has been segmented into North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, China, Japan and Middle East & Africa. North America is estimated to dominate the global carpal tunnel release systems market with maximum value share of the overall market in 2017. The North America carpal tunnel release systems market is estimated to increase at a CAGR of 3.6% over the forecast period to reach the value of US$ 221.6 Mn. Emergence of several regional market players, a robust distribution network, and well-developed healthcare infrastructure in North America are some of the key factors driving the revenue growth of the carpal tunnel release systems market in North America.

Competitive Landscape
Some of the top players operating in the global carpal tunnel release systems market such as Stryker Corporation, Arthrex, Inc., MicroAire Surgical Instruments, LLC., S.E.G-WAY Orthopaedics Inc., Smith & Nephew plc, Integra LifeSciences Corporation, AM Surgical Inc., SONEX HEALTH, LLC., Medical Designs, LLC, CONMED Corporation, Innomed, Inc., , LB Medical LLC., S2S Surgical LLC, Endodoctor GmbH. Leading manufacturer of carpal tunnel release systems are focusing on collaboration to promote the use of carpal tunnel release systems for the treatment of carpal tunnel syndrome. Some companies are focusing collaborate directly with hospitals to promote their carpal tunnel release systems. On other hand, few players of carpal tunnel release systems are emphasis on collaboration with distributors to expand their regional presence.

For More Information: https://www.futuremarketinsights.com/reports/sample/rep-gb-5965

Unique System Makes Hospitals and Clinics Accessible for the Blind and Visually Impaired http://www.hhmglobal.com/industry-updates/press-releases/unique-system-makes-hospitals-and-clinics-accessible-for-the-blind-and-visually-impaired Tue, 18 Sep 2018 05:20:42 +0000 http://www.hhmglobal.com/?p=15333 RightHear, developer of an innovative solution for accessibility and orientation of blind and visually impaired persons, announced a dedicated version of the system for hospitals and clinics, making them accessible to people with sight impairments and allowing them to orient themselves independently inside the hospital/clinic. The announcement follows a successful implementation in four Israeli hospitals: Assuta Ramat HaHayal, Assuta Ashdod, Herzliya Medical Center and HaEmek Medical Center.

RightHear addresses the accessibility, orientation and navigation needs of blind and visually impaired persons (as well as orientation challenged individuals), providing them with real-time audio descriptions, through their own smartphone, about their precise indoor location, directing them and narrating their surroundings. The voice notifications are based on information received from Bluetooth beacons (sensors) located in the area. The sensors are installed by the on-site staff, by simply attaching them to the wall with a sticker.

The hospital/clinic dedicated solution implements lessons learned at the Israeli hospitals that deployed the system. Lessons learned include location of the sensors and scripts of various instructions given to the blind/visually impaired persons, directing them during their visit to the hospital or clinic, or even hospitalization.

The smartphone app alerts users whenever they are near a RightHear-enabled hospital/clinic and picks up the signals automatically from the beacons. When the user approaches the hospital/clinic, she/he is told where the entrance is, and is directed by audio descriptions to the various departments, outpatient clinics, elevators, counters, etc. The user is alerted when he/she reaches the desired department and floor, and then, inside the department, he/she is directed to the various counters and rooms.

In addition, the system includes an administrator dashboard, allowing the staff to program and control the system optimally, according to the needs of blind and visually impaired visitors.

“Blind and visually impaired persons come to hospitals and clinics both as patients and as visitors. Today, they usually need guidance to orient themselves in the vast space of hospitals or large clinics. RightHear’s system allows them to move and orient themselves independently,” said Idan Meir, RightHear’s CEO. “Hospital/clinic managers can set the administrator dashboard to a maximum level of detail in every department and corridor.”

The RightHear system is suitable for any type of building, including complex buildings (interconnected buildings) like malls, corporations, universities, hospitals, municipalities, airports, museums, supermarkets, hotels, restaurants, QSRs and more.